Publications
89
Citations
1,070
Est. group size
~5
Recurring co-author estimate
Active years
23
Publishing since 2004
Typically publishes in teams of ~18 · 14% small-team papers (≤3 authors) · across 22 venues
- Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool
Clinical Cancer Research · 2026
- Current experiences with teclistamab in patients with multiple myeloma and renal impairment
Expert Review of Hematology · 2025
- Dexamethasone for management of cytokine release syndrome (CRS) associated with talquetamab in patients with Relapsed/Refractory multiple myeloma
Blood · 2025
- Supportive care alone is effective for managing low-grade CRS in multiple myeloma patients treated with bispecific antibodies
Blood · 2025
- MM-216: Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome and Outpatient Dosing of Talquetamab in Relapsed/Refractory Multiple Myeloma: Updated Phase 1/2 Monumental-1 Results
Clinical Lymphoma Myeloma & Leukemia · 2025
- Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study
Blood · 2025
- Predictors of frontline doublet or triplet regimen initiation in transplant-ineligible newly diagnosed multiple myeloma
Future Science OA · 2025
- Refining renal response assessment in monoclonal immunoglobulin deposition disease: Challenges, limitations and need for consensus
Leukemia · 2025
- POSTER: MM-216 Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome and Outpatient Dosing of Talquetamab in Relapsed/Refractory Multiple Myeloma: Updated Phase 1/2 Monumental-1 Results
Clinical Lymphoma Myeloma & Leukemia · 2025
- eMMpower: A Longitudinal Multi-Center Chart Review Consortium for Multiple Myeloma (MM)
Clinical Lymphoma Myeloma & Leukemia · 2025
- Supplementary Data TS1-4 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
2025
- Supplementary fig 1 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
2025
- Surzetoclax (ABBV-453) in combination with daratumumab and dexamethasone in biomarker-selected patients with Relapsed/Refractory multiple myeloma: A Phase 1/2, multicenter, open-label platform study
Blood · 2025
- Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial
Nature Cancer · 2024
- Administration of teclistamab in four patients with multiple myeloma requiring hemodialysis
Journal of Oncology Pharmacy Practice · 2024
- Blood×19
- Clinical Lymphoma Myeloma & Leukemia×10
- Leukemia & lymphoma/Leukemia and lymphoma×5
- Journal of Clinical Oncology×4
- Clinical Cancer Research×3
- Rafat Abonour
Medicine · Indiana University
- Attaya Suvannasankha
Medicine · Indiana University
- Erica Campagnaro
Medicine · University of Michigan
- Brian A. Walker
Medicine · Indiana University
- Camille Herzog
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile